CoChat

Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users

Open access
Grebely, Jason, Raffa, Jesse D, Meagher, Caite, Duncan, Fiona, Genoway, Krista A, Khara, Milan, McLean, Mark, Mead, Annabel, Viljoen, Mark, DeVlaming, Stanley, Fraser, Chris, Conway, Brian · 2007 · Journal of Gastroenterology and Hepatology
Cited by 75

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background and Aim: There are few studies investigating the treatment of hepatitis C virus (HCV) infection in current and former drug users. With this in mind, we sought to evaluate the antiviral efficacy of interferon alpha‐2b (IFN α‐2b) or pegylated‐interferon alpha‐2b (PEG‐IFN α‐2b) and ribavirin (RBV) in injection drug users (IDU) enrolled in a directly observed therapy (DOT) program, as measured by sustained virologic response (SVR). Methods: Viremic HCV‐infected IDU, with alanine aminotransferase (ALT) >1.5× upper limit of normal (ULN) were offered 24–48 week (based on HCV genotype) therapy with RBV (800–1200 mg/day, based on weight) along with IFN α‐2b (3 million IU thrice weekly) replaced by PEG‐IFN α‐2b (1.5 ìg/kg once weekly) as it became available. All injections were directly observed. The primary endpoint was SVR. Results: Overall, 40 patients (33 males) received IFN α‐2b (12) or PEG‐IFN α‐2b (28), 55% with HCV genotypes 2 or 3. Only 14 discontinued therapy, 5 due to toxicity, 6 due to illicit drug use and 3 did not achieve an early virologic response. In an intent‐to‐treat analysis, the overall SVR was 55% (22/40), 64% (14/22) in subjects with genotypes 2/3. There was no significant difference in response rates among those with >6 (50%) or ≤6 months (64%) drug abstinence (P = 0.51) or among those with (53%) and without (57%) intercurrent drug use (P = 0.99); however, frequent users (n = 9) had a decreased SVR (22%) when compared with occasional users (n = 10, 80%,P = 0.12). Conclusion: Treatment of HCV in current and former IDU within a multidisciplinary DOT program can be successfully undertaken, resulting in SVR similar to those in randomized controlled trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1440-1746.2007.05032.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 75

Metadata

Authors
Grebely, J., Raffa, J. D., Meagher, C., Duncan, F., Genoway, K. A., Khara, M., McLean, M., Mead, A., Viljoen, M., DeVlaming, S., Fraser, C., & Conway, B.
Venue
Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
2007-08-15
Volume
22
Issue
9
Pages
1519-1525
ISSN
  • 0815-9319 (ISSN-L)
  • 1440-1746
OpenAlex
W2081569952
Cited by
75
References
2
FWCI
5.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. https://app.cochat.ai/papers/10.1111/j.1440-1746.2007.05032.x
The paper
Grebely, J., Raffa, J. D., Meagher, C., Duncan, F., Genoway, K. A., Khara, M., McLean, M., Mead, A., Viljoen, M., DeVlaming, S., Fraser, C., & Conway, B. (2007). Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/j.1440-1746.2007.05032.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.